Does this mean native GLP-1 does not affect appetite?

It affects meal size, which is an appetite effect within a meal. What the knockdown showed is that removing the receptors did not disturb long-term energy balance in normally eating animals - a statement about body weight over time, not about within-meal satiation.

Do GLP-1 drugs work through the vagus too?

Partly, and the relative contribution of vagal and direct central routes is still argued. The point of the knockdown result is that the vagal route alone does not account for sustained weight change, which is what the drugs produce.

Why is exendin(9-39) used to confirm the response?

It is a GLP-1 receptor antagonist. If a response disappears when the receptor is blocked, the response was mediated by that receptor rather than by something incidental - the same logic as a knockout, applied pharmacologically and reversibly.

Was the knockdown complete?

No, and the authors are careful about this: it was a knockdown rather than a knockout, so residual receptor expression remained. That makes the positive findings - meal size, gastric emptying, glycaemia - robust, and means the absence of a long-term weight effect should be read as an absence under partial reduction.

GLP-1 & Incretin Science

The Nerve That Reads GLP-1 Before the Blood Does

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-243 cited sources

Native GLP-1 acts largely on receptors sitting on vagal afferent nerve endings close to where it is released. Knocking those receptors down in rats increased meal size and accelerated gastric emptying, while leaving long-term energy balance under normal eating intact.

Key facts

Receptor location: Vagal afferent neurons, nodose ganglion
Native GLP-1 circulating half-life: Minutes, cleaved by DPP-4
Knockdown effect on meal size: Increased
Knockdown effect on gastric emptying: Accelerated
Knockdown effect on postmeal glycaemia: Elevated
Knockdown effect on insulin release: Blunted
Knockdown effect on long-term energy balance: None under normal eating
Term used by the authors: Neuroincretin effect

Why the route matters more than it sounds

Native GLP-1 is destroyed within minutes of release by DPP-4, and a substantial fraction is cleaved before it even leaves the intestinal circulation. That creates a problem for the textbook picture of a hormone travelling through the bloodstream to distant targets: for most of what GLP-1 does physiologically, not enough of it survives the journey. The resolution is that much of its action is local. GLP-1 receptors sit on the terminals of vagal afferent nerves in the gut wall, close to where the hormone is released, and signalling through those terminals reaches the brainstem as nerve traffic rather than as circulating peptide.

The knockdown experiment

Krieger and colleagues knocked down GLP-1 receptors specifically on vagal afferent neurons in rats and measured what changed. Three things did. Meal size increased. Gastric emptying accelerated. Postmeal glycaemia was elevated and insulin release was blunted, which the authors describe as evidence that these receptors are physiological contributors to what they call the neuroincretin effect after a meal. That is a coherent picture of a within-meal control system: the gut detects nutrients, releases GLP-1 locally, the vagus reports it, and the response slows gastric emptying, limits the meal and primes insulin release.

And the thing that did not change

Long-term energy balance. The authors state that a full expression of vagal afferent GLP-1 receptors is not necessary for the maintenance of long-term energy balance under normal eating conditions. Removing most of the receptors through which native GLP-1 acts did not make the animals fat. That is the single most important sentence in this literature for anyone trying to reason about what GLP-1 drugs do, and it is almost never quoted.

What it implies about the drugs

If native GLP-1 signalling through its principal physiological route does not set body weight, then a drug that does set body weight is not doing so by restoring or amplifying that route. The pharmacological agents differ from the hormone in three ways at once: they resist DPP-4, so they survive to circulate; they are engineered to persist for days rather than minutes, so exposure is continuous rather than postprandial; and continuous circulating exposure reaches central GLP-1 receptors that a locally released, rapidly degraded hormone largely does not. The drug is not a bigger dose of the physiology. It engages a different part of the system, continuously, at concentrations the body never produces.

A related finding about synergy

Iwasaki and colleagues recorded from nodose ganglion neurons and found that GLP-1 and insulin synergistically activate vagal afferents. Responses to GLP-1 were blocked by the antagonist exendin(9-39), confirming they were receptor-mediated, and 92% of GLP-1-responsive neurons also responded to insulin. At low concentrations of each, neither did much alone, but the two in combination recruited previously unresponsive neurons and produced larger responses in responsive ones. That is a plausible mechanism for how two postprandial signals arriving together are read as more than either alone, and it is a reminder that these afferents integrate rather than simply relay.

How to use this when reading a claim

Any statement of the form 'this raises your natural GLP-1' is a claim about the pathway described here: local release, rapid degradation, vagal signalling, within-meal effects. It is not a claim about the pathway a GLP-1 receptor agonist engages, and the knockdown result indicates the two are not on the same continuum with respect to body weight. Licensed GLP-1 receptor agonists are prescription medicines; nothing supplied on this site is a version of one, an alternative to one, or a way of achieving what one achieves.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Does this mean native GLP-1 does not affect appetite?: It affects meal size, which is an appetite effect within a meal. What the knockdown showed is that removing the receptors did not disturb long-term energy balance in normally eating animals - a statement about body weight over time, not about within-meal satiation.
Do GLP-1 drugs work through the vagus too?: Partly, and the relative contribution of vagal and direct central routes is still argued. The point of the knockdown result is that the vagal route alone does not account for sustained weight change, which is what the drugs produce.
Why is exendin(9-39) used to confirm the response?: It is a GLP-1 receptor antagonist. If a response disappears when the receptor is blocked, the response was mediated by that receptor rather than by something incidental - the same logic as a knockout, applied pharmacologically and reversibly.
Was the knockdown complete?: No, and the authors are careful about this: it was a knockdown rather than a knockout, so residual receptor expression remained. That makes the positive findings - meal size, gastric emptying, glycaemia - robust, and means the absence of a long-term weight effect should be read as an absence under partial reduction.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum